PDCD1LG2 and melanoma: Treatment of malignant melanoma can include immune checkpoint blockade (ICB) with monoclonal antibodies against T cell-expressed immune checkpoint receptor PD1, blocking PD-L1 and PD-L2 binding to limit tumor-induced immune tolerance19.